Human Genome's Resistance To $2.6B GSK Offer Draws Fire

Law360, New York (May 29, 2012, 1:53 PM ET) -- A shareholder of Human Genome Sciences Inc. on Friday asked a Maryland state court to block the biotech company's efforts to derail a $2.59 billion takeover attempt by British drugmaker GlaxoSmithKline PLC.

Plaintiffs in a putative class action filed last month in Montgomery County court are now seeking a temporary restraining order that would kill a poison pill meant to deter GSK's advances.

Human Genome, which makes gene-targeting medicines, rejected GSK's offer in April as too low and on May 17 launched a shareholder-rights plan to...
To view the full article, register now.